Bissler JJ and colleagues demonstrated everolimus, a mammalian target of rapamycin (mTOR) inhibitor, could significant reduction in renal angiomyolipoma volume compared with placebo in Western populations [8]. Here, MTOR is linked to kidney angiomyolipoma.